RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit

RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire

BENSALEM, Pa., Feb. 3, 2022

BENSALEM, Pa., Feb. 3, 2022 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).

Class Period: November 25, 2019 – October 11, 2021
Lead Plaintiff Deadline: February 8, 2022

Investors suffering losses on their Revance investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) quality control deficiencies existed at the Company's manufacturing facility for DAXI; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; (3) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/rvnc-investors-have-opportunity-to-lead-revance-therapeutics-inc-securities-fraud-lawsuit-301474936.html

SOURCE Law Offices of Howard G. Smith

Copyright CNW Group 2022